Abstract: Vancomycin is a glycopeptide antibiotic used to treat Gram-positive infections including methicillin-resistant Staphylococcus aureus (MRSA). The objectives of this study were to evaluate the appropriateness of the initial dosing regimen of vancomycin, identify factors to be considered in regimen selection and develop a new dosing nomogram. Therapeutic drug monitoring (TDM) data of vancomycin obtained from Seoul National University Hospital from 2011 to 2013 were included in this analysis. The vancomycin trough concentrations at steady-state were estimated using Abbott's PKS software program and then categorized into three levels: subtherapeutic, therapeutic and toxic. The newly developed nomograms were evaluated by analysing the percentage of patients with target vancomycin trough concentration using the data of 2,570 patients of the first TDM cases. Therapeutic level was achieved only in approximately one-fifth of the cases, while 56.0% and 23.8% of the TDMs were considered subtherapeutic and toxic, respectively. As body-weight and creatinine clearance (CrCL) increased, the proportion of patients with a subtherapeutic level increased. Using the newly developed nomogram increased the proportion of patients who achieved therapeutic levels from 23.1% to 45.0% or 13.8% to 36.2% (target, 10-15 and 15-20 mg/L, respectively). These results suggest that the vancomycin concentrations fail to reach the therapeutic level or exceed the safe upper margin of the therapeutic level depending on age, body-weight and CrCL. Considering these factors, the new nomograms provide a strategy to achieve target concentrations of vancomycin more rapidly than existing regimens.
Vancomycin is a glycopeptide antibiotic used to treat Gram-positive infections including methicillin-resistant Staphylococcus aureus (MRSA), and its use is increasing [1, 2] . Staphylococcus aureus is a commonly isolated organism in Korea [3] , and the proportion of MRSA cases in Korea is higher than that in other countries [4, 5] . Vancomycin has a narrow therapeutic index, which is defined as a small difference between the therapeutic and toxic doses [6] [7] [8] [9] . Drugs with narrow therapeutic indexes easily achieve subtherapeutic or toxic drug concentrations because small changes in the dosage can lead to significant changes in drug responses [7] . Therefore, the dosage of these drugs should be individualized based on various patient characteristics, especially advanced age and comorbidities. Monitoring of drug concentrations has been recommended to optimize drug concentrations for narrow therapeutic index drugs.
Based on the new guideline recommendations on therapeutic drug monitoring (TDM) of vancomycin issued in 2009 [10] , trough serum vancomycin concentrations should be maintained above 10 mg/L to avoid the development of resistant strains. For complicated infections such as endocarditis, osteomyelitis, meningitis and hospital-acquired pneumonia caused by S. aureus, vancomycin serum trough concentrations of 15-20 mg/L are recommended to improve penetration, increase the probability of obtaining optimal target serum concentrations and improve clinical outcome. In accordance with these guidelines, several published articles suggested new dosage regimens or nomograms for patient groups with specific CrCL rates and weights to achieve these serum vancomycin concentrations [11] [12] [13] [14] [15] [16] [17] . Most of these studies developed nomograms only for the high vancomycin target concentrations (15-20 mg/L) and restricted study populations to patients with certain body-weights or CrCL rates or excluded unstable patients.
The objectives of this study were to evaluate the appropriateness of the initial dosing regimen used in the local clinical practice for vancomycin by analysing the results of therapeutic drug concentration monitoring. Furthermore, we sought to identify factors to be considered when choosing the dosing regimen of vancomycin and suggest a new nomogram to achieve therapeutic concentrations of vancomycin for complicated and non-complicated infections in various patient populations.
Materials and Methods
This retrospective study was conducted at Seoul National University Hospital (SNUH) in Seoul, Korea. SNUH is a 1800-bed tertiary teaching hospital where almost 10,000 TDM case consultations are requested yearly, and approximately 50% of these involve vancomycin TDM. Vancomycin TDM consultations performed from 2011 to 2013 were included in the analysis. This study was approved by the institutional review board of the hospital.
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Patients and data collection. Data of first TDM consultation cases of patients who were aged ≥18 years and treated with intravenous (IV) vancomycin were collected from the electronic medical record (EMR) system of SNUH ( fig. 1 ). Patients meeting any of the following criteria were excluded as follows: age <18 years; lack of demographic data or serum creatinine level; and inaccurate information on dosing regimen or concentration of vancomycin.
Demographic data such as age, sex, body-weight and serum creatinine level were collected. Information on vancomycin dosage regimens including exact dates and time of dosing and sampling was also collected. The CrCL was estimated using the Cockcroft-Gault equation.
Pharmacokinetic (PK) and statistical analysis. Vancomycin serum concentrations were determined using chemiluminescent microparticle immunoassay (Architect Integrated Systems, Abbott Laboratories, Abbott Park, IL, USA). The lower limit of quantification was 0.3 mg/L. The assay was designed to have a precision of <10% total coefficients of variation, and the within-laboratory precision estimate was <10%.
The trough concentrations at steady-state were estimated using the Abbott's PKS software program. The exact dosing and sampling times recorded in the EMR system were used to estimate the trough concentration. Estimated vancomycin trough concentrations were categorized into three levels: subtherapeutic, therapeutic and toxic. Depending on the vancomycin indications, concentration ranges of 10-15 and 15-20 mg/L were considered the therapeutic levels.
The statistical analysis system (SAS) version 9.3 (SAS Institute, Cary, NC, USA) was used for the statistical analysis. A multiple linear regression method was used to identify relationship between demographic data and vancomycin trough concentrations. We developed the equation for estimating vancomycin pharmacokinetic (PK) parameters such as volume of distribution (V d ) and clearance (CL) using the linear regression method. A chi-square test was used to compare the proportion of vancomycin levels among subgroups of age, body-weight, CrCL and sex, while a p < 0.05 was considered statistically significant.
Nomogram development and evaluation. Two data sets of 485 and 410 patients from the original data set were selected as nomogram development and test sets, respectively. Firstly, we calculated the dose and intervals (first nomogram) to achieve target vancomycin concentrations for each body-weight and CrCL group using the PK parameter estimation equation and Equation 1. The dosing intervals were fixed to 6, 8, 12 or 24 hr, and the doses were subsequently calculated.
where C trough = trough concentration, k = elimination rate constant and s = dosing interval. Secondly, we calculated the dose and intervals for each individual patient in the nomogram development set, and the first nomogram was modified to obtain a final nomogram that enabled a greater proportion of patients in the development set to achieve target vancomycin concentration. The trough vancomycin concentrations were estimated for the nomogram test set of 410 patients using the final nomogram, and the proportion of patients in each level was summarized.
Results

Evaluation of initial dosing regimen and the relationship between demographic data and vancomycin concentrations.
A total of 3986 cases were first-request consultation cases, while the others were follow-up cases ( fig. 1 ). Cases with inaccurate or absent data were excluded, and 2570 cases were included in the final analysis. The mean patient age was 58.7 years, and 61.7% were male patients (table 1) . Approximately one-third of patients (774, 30.1%) had complicated infections such as bacteraemia induced by S. aureus and infections caused by MRSA. More than half of the patients (1438, 56.0%) had subtherapeutic vancomycin concentration levels, and the most common initial vancomycin regimen (1750, 68.1%) was 1000 mg every 12 hr (2000 mg daily dose, table 2). Among the patients administered a fixed dose regimen of 2000 mg daily, subtherapeutic, therapeutic and toxic levels were found in 51.3%, 22.3% and 26.4%, respectively.
As body-weight increased, the proportion of patients who reached the target range of vancomycin decreased. Specifically, 70% of patients with a body-weight >80 kg had subtherapeutic levels of vancomycin, indicating that they might have been insufficiently treated ( fig. 2) . Among the patients with CrCL > 60 mL/min/kg, more than half did not achieve therapeutic concentrations of vancomycin. In contrast, a higher proportion of patients with renal impairment (i.e. CrCL < 60 mL/min/kg) had toxic levels of vancomycin. Men were more likely than women to have subtherapeutic levels. With increasing age, the proportion of patients with subtherapeutic levels decreased, and the proportion of toxic levels increased as follows: 40% TDMs of those aged >80 years were considered toxic, and all these differences were statistically significant.
To evaluate the demographic characteristics that could be related to vancomycin concentrations, a stepwise multiple linear regression analysis was performed. This showed that dosenormalized vancomycin trough concentrations were correlated with sex, age, body-weight and creatinine clearance ( fig. 3) . In comparison, when we applied the newly developed nomogram, this percentage increased to 45.0 and 36.2 for nomograms (a) and (b), respectively. We also compared the new nomogram to the one previously developed for Taiwanese patients [12] and found that a smaller percentage of patients achieved therapeutic levels (29.6%) and a larger percentage of patients achieved subtherapeutic levels (47.9%) in the Taiwanese study than those in the present study.
Discussion
In this study, we evaluated the appropriateness of the initial dosing regimen for vancomycin, identified factors that affect vancomycin trough concentrations and developed new nomograms for vancomycin. When administering vancomycin, most clinicians use the fixed dosing regimen of 1000 mg vancomycin every 12 hr, which is the recommended dose for adults on the drug product label [18] . More than half of the patients administered vancomycin on a fixed dosing regimen (51.3%) failed to reach therapeutic levels. Patients with a higher body-weight and normal renal function were more likely to have a subtherapeutic level, implying that the fixed dosing regimen of 1000 mg every 12 hr, which does not consider CrCL or the body-weight of patients, might not be appropriate in these patients. Patients with a higher bodyweight, a normal renal function, or complicated infections need a higher target trough concentration of 15-20 mg/L. Four variables were identified to have linear relationship with vancomycin trough concentrations and also affect the frequency and percentage of vancomycin trough concentration levels. As body-weight and CrCL increased, the proportion of patients with subtherapeutic vancomycin levels also increased. This finding was expected based on the PK characteristics of vancomycin: V d is proportional to body-weight, and the relationship between vancomycin CL and CrCL is linear [12, 19] . Although sex and age affected the steady-state concentrations of vancomycin, these effects might be related to differences in body-weight or CrCL.
At SNUH, most clinicians prescribing vancomycin requested TDM consultation services. Often, the first vancomycin concentrations were subtherapeutic, and the dose of vancomycin was increased after the consultation, with the serum concentration eventually reaching therapeutic levels. Approximately 74% of the consultation cases in this study were requested within 2-4 days after initiating vancomycin therapy, and the time to reach steady-state can be a few more days in patients with a decreased renal function, based on the half-life of vancomycin [18] . These delays in reaching therapeutic concentrations could lead to a failure in infection control and the development of resistant pathogens. Therefore, it is important for the initial dosing regimen to be appropriate. Furthermore, an initial loading-dose would contribute to reducing the delay in achievement of the therapeutic level.
Using the new nomograms increased the proportion of patients who achieved therapeutic levels from 23.1% to 45.0% and 13.8% to 36.2% (target, 10-15 and 15-20 mg/L, respectively). These success rates were comparable to those of other nomograms where the percentage of patients in the target range was between 41.2 and 58.0 [11] [12] [13] [14] [15] 17] . Although our nomogram increased the percentage of the patients who achieved therapeutic levels of vancomycin, more than half of the patients had subtherapeutic or toxic vancomycin levels. Although the dosage regimen was adjusted for body-weight and CrCL, the variability in vancomycin concentration was still high because vancomycin is known to have a narrow therapeutic range [6] [7] [8] [9] . Therefore, TDM for vancomycin is still necessary, even after choosing an appropriate initial dosing regimen. Values are dose (mg)/dosing interval (hr) for each group (e.g. 500/12 represents 500 mg q12 hr). 1 CrCL was calculated using Cockcroft-Gault equation.
This study had some limitations, which are worth mentioning. For example, this was a retrospective study, and the vancomycin trough level was estimated; therefore, the results could differ when the nomograms are applied. In addition, this nomogram could not be applied to patients with severe renal impairment and with CrCL < 30 mL/min or body-weight >90 kg. Developing a nomogram for children is also necessary.
Conclusion
When the conventional initial dosing regimen was followed, the therapeutic level of vancomycin was achieved only in approximately one-fifth of cases. As age, body-weight and CrCL affected the concentrations of vancomycin, its dosing regimen should be carefully chosen accounting for all these factors. Finally, the new nomograms might facilitate the achievement of target concentrations of vancomycin more rapidly than existing regimens do.
